Neuphoria Therapeutics Inc.
NEUP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $14 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$14 | $1 | $1 |
| Revenue | $0 | -$0 | $0 | $0 |
| % Growth | 100% | -165.6% | 2,130.1% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | 97.9% | 98.9% | 0% |
| EBITDA | -$0 | -$1 | $0 | -$0 |
| % Margin | – | 5,406.5% | 75.6% | -291.5% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | 2,414.3% | 75.1% | -293.2% |
| EPS Diluted | -4.41 | -6.77 | 6.55 | -0.008 |
| % Growth | 34.9% | -203.4% | 79,015.7% | – |
| Operating Cash Flow | -$0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | $0 | $0 | -$0 |